Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1326-1334

  Tyagi, Shilpa ^a   Bhui, Kulpreet ^a   Singh, Richa ^a   Singh, Madhulika ^a   Raisuddin, Sheikh ^b   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

A431 cells; Cisplatin; P73 ; Plk; Squamous cell carcinoma

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; POLO LIKE KINASE 1; PROTEIN P53; PROTEIN P73; PROTEIN TYROSINE PHOSPHATASE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; EPIDERMOID TUMOR; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; UPREGULATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; GENETICS; HUMAN; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA-BINDING PROTEINS; GENES, P53; HUMANS; MUTATION; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 77956651477     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.025     Document Type: Article

References (34)

1. WHO, World Health Organization, 4th May 2010. http://www.who.int/uv/faq/skincancer/en/index1.html.
2. Hamasaki V.K., Vokes E.E. Chemotherapy in head and neck cancer. Curr Opin Oncol 1992, 4:1376-1384.
3. Adelstein D.J., Sharan V.M., Earle A.S., Shah A.C., Vlastou C., Haria C.D., et al. Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol 1990, 13:440-447.
4. Pace A., Savarese A., Picardo M., Maresca V., Pacetti U., Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003, 21:927-931.
5. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993, 103:1-52.
6. Schmit T.L., Zhong W., Nihal M., Ahmad N. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009, 8:2697-2702.
7. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
8. Liu X., Erikson R.L. Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5789-5794.
9. Matthess Y., Kappel S., Spänkuch B., Zimmer B., Kaufmann M., Strebhardt K. Conditional inhibition of cancer cell proliferation by tetracycline-responsive. H1 promoter-driven silencing of PLK1. Oncogene 2005, 24:2973-2980.
10. Chen X.H., Lan B., Qu Y., Zhang X.Q., Cai Q., Liu B.Y., et al. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol 2006, 12:29-35.
11. Guan R., Tapang P., Leverson J.D., Albert D., Giranda V.L., Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005, 65:2698-2704.
12. Schmit T.L., Zhong W., Setaluri V., Spiegelman V.S., Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009, 129:2843-2853.
13. Spänkuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004, 96:862-872.
14. Degenhardt Y., Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010, 16:384-389.
15. Jimeno A., Rubio-Viqueira B., Rajeshkumar N.V., Chan A., Solomon A., Hidalgo M. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2010, 9:311-318.
16. Mross K., Frost A., Steinbild S., Hedbom S., Rentschler J., Kaiser R., et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008, 26:5511-5517.
17. Liu X., Lei M., Erikson R.L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006, 26:2093-2108.
18. van Vugt M.A., Bràs A., Medema R.H. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res 2005, 65:7037-7040.
19. Lansing T.J., McConnell R.T., Duckett D.R., Spehar G.M., Knick V.B., Hassler D.F., et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007, 6:450-459.
20. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003, 22:7486-7495.
21. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402.
22. Ozaki T., Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005, 96:729-737.
23. Lokshin M., Tanaka T., Prives C. Transcriptional regulation by p53 and p73. Cold Spring Harb Symp Quant Biol 2005, 70:121-128.
24. Harms K., Nozell S., Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004, 61:822-842.
25. Arora A., Kalra N., Shukla Y. Regulation of p21/ras protein expression by diallyl sulfide in DMBA induced neoplastic changes in mouse skin. Cancer Lett 2006, 242:28-36.
26. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
27. Lowry O.H., Rosenbrough N.K., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
28. Arora A., Shukla Y. Induction of apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors. Nutr Cancer 2002, 44:89-94.
29. Anderson H.J., Andersen R.J., Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003, 5:423-430.
30. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3:513-519.
31. Shi Z., Azuma A., Sampath D., Li Y.X., Huang P., Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 2001, 61:1065-1072.
32. Kim S.A., Kwon S.M., Yoon J.H., Ahn S.G. The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells. Int J Oncol 2010, 36:867-872.
33. Koida N., Ozaki T., Yamamoto H., Ono S., Koda T., Ando K., et al. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 2008, 283:8555-8563.
34. Dar A.A., Belkhiri A., Ecsedy J., Zaika A., El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008, 68:8998-9004.